Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin
- PMID: 3119815
- DOI: 10.1007/BF01066522
Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin
Abstract
A model comprising six compartments, a systemic and presystemic compartment for nitroglycerin and each of its two dinitrate metabolites is presented to describe the interrelationships between plasma concentrations of the two metabolites and metabolism in skin after intravenous and transdermal ointment administration of nitroglycerin. Using a perfusion-limited pharmacokinetic model, the equation for the calculation of the fraction (F) of the dose of nitroglycerin systemically available from skin was derived independent of nitroglycerin plasma concentrations. Estimated F values (0.68-0.76) are comparable to values reported in Rhesus monkeys (0.80-0.84). Simulated plasma concentration-time profiles were reasonably fitted to the observed concentrations of nitroglycerin and its two metabolites after transdermal administration. This preliminary model suggests that transdermal bioavailability for a drug metabolized in the skin can be reasonably estimated.
Similar articles
-
Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations.Pharm Res. 1991 Jun;8(6):744-9. doi: 10.1023/a:1015802101272. Pharm Res. 1991. PMID: 1905809
-
Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism.J Pharm Sci. 1983 Jul;72(7):745-8. doi: 10.1002/jps.2600720708. J Pharm Sci. 1983. PMID: 6411893
-
Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure.Am J Med. 1986 Nov;81(5):765-70. doi: 10.1016/0002-9343(86)90341-4. Am J Med. 1986. PMID: 3096133 Clinical Trial.
-
[Transdermal use of nitroglycerin].Folia Med Cracov. 1989;30(1-2):13-21. Folia Med Cracov. 1989. PMID: 2518362 Review. Polish.
-
Transdermal delivery of drugs.Annu Rev Med. 1988;39:221-9. doi: 10.1146/annurev.me.39.020188.001253. Annu Rev Med. 1988. PMID: 3130771 Review.
Cited by
-
Novel pharmacokinetic modelling of transdermal nitroglycerin.Pharm Res. 1998 Apr;15(4):614-9. doi: 10.1023/a:1011942213508. Pharm Res. 1998. PMID: 9587959
-
Variational analysis of the transdermal delivery rate from two prototypical ethanol-water nitroglycerin TTS devices and Transderm-Nitro 10 in the normal population.J Pharmacokinet Biopharm. 1992 Oct;20(5):443-59. doi: 10.1007/BF01061465. J Pharmacokinet Biopharm. 1992. PMID: 1287196 Clinical Trial.
-
Effect of pre-treatment with transdermal glyceryl trinitrate on myocardial ischaemia during coronary angioplasty.Heart. 1996 Dec;76(6):471-6. doi: 10.1136/hrt.76.6.471. Heart. 1996. PMID: 9014793 Free PMC article. Clinical Trial.
-
Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations.Pharm Res. 1991 Jun;8(6):744-9. doi: 10.1023/a:1015802101272. Pharm Res. 1991. PMID: 1905809
-
Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.Br J Clin Pharmacol. 1991 Jun;31(6):671-6. doi: 10.1111/j.1365-2125.1991.tb05591.x. Br J Clin Pharmacol. 1991. PMID: 1678271 Free PMC article. Clinical Trial.